Reference number : GC-2017-Q4-00909, amendment number : , agreement type : G, recipient legal name : Khafipour, Ehsan (University of Manitoba)|Khafipour, Ehsan (Université du Manitoba), recipient country : CA, recipient province : nan, recipient city : Manitoba, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietary_x000D_
supplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietary_x000D_
carbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has been_x000D_
investigated in the past years for its effects on gut health via balancing the microbiota composition and short_x000D_
chain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology through_x000D_
modification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects on_x000D_
mucosal barrier system._x000D_
MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRS_x000D_
product named MSPrebiotic®. The company is seeking a project to optimize their recommendations for_x000D_
administration of MSPrebiotic® either as a preventative and/or therapeutic tool for reducing gut inflammation_x000D_
and improving gut health._x000D_
Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic®) in a pig model of_x000D_
experimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducing_x000D_
diet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRS_x000D_
diet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (to_x000D_
measure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measures_x000D_
of gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gut_x000D_
microbiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction of_x000D_
functional capacity of the microbial community using PICRUSt. The outcome of this research will help the_x000D_
company to optimize their recommendations for the use of MSPrebiotic® as a preventative and/or therapeutic_x000D_
approach for reducing gut inflammation and improving gut health., program purpose french : Emerging therapeutics are used to alleviate intestinal inflammation and microbial dysbiosis including dietary_x000D_
supplies of prebiotics and probiotics. Digestion resistant starch (DRS) represents a diverse range of dietary_x000D_
carbohydrates bypassing into the lower gut where it undergoes microbial fermentation. DRS has been_x000D_
investigated in the past years for its effects on gut health via balancing the microbiota composition and short_x000D_
chain fatty acid levels. It is speculated that DRS can reduce colitis symptoms and pathology through_x000D_
modification of the gut microbiota, possible regulation of local inflammatory cytokines and its effects on_x000D_
mucosal barrier system._x000D_
MSPrebiotic Inc., a Manitoba-based global biotechnological company, has developed a popular potato DRS_x000D_
product named MSPrebiotic®. The company is seeking a project to optimize their recommendations for_x000D_
administration of MSPrebiotic® either as a preventative and/or therapeutic tool for reducing gut inflammation_x000D_
and improving gut health._x000D_
Here, we investigate the protective and therapeutic effects of DRS (MSPrebiotic®) in a pig model of_x000D_
experimental colitis. Pigs will receive 5 different treatments including 1) basal control diet, 2) colitis-inducing_x000D_
diet (1% carrageenan gum), 3) DRS diet, 4) colitis-inducing diet for 2 weeks followed by introduction of DRS_x000D_
diet (to measure therapeutic effect of DRS), and 5) DRS diet for 2 weeks followed by a colitis-inducing diet (to_x000D_
measure the protective effect of DRS). Fecal consistency and large intestine histology will be used as measures_x000D_
of gastrointestinal inflammation. Blood samples will be analyzed for systemic inflammatory markers. Gut_x000D_
microbiota profile will be assed using 16S rRNA gene sequencing in-house followed by prediction of_x000D_
functional capacity of the microbial community using PICRUSt. The outcome of this research will help the_x000D_
company to optimize their recommendations for the use of MSPrebiotic® as a preventative and/or therapeutic_x000D_
approach for reducing gut inflammation and improving gut health., agreement title english : Protective and therapeutic use of digestion resistant starch (MSPrebiotic®) in a pig model of experimental colitis, agreement title french : Protective and therapeutic use of digestion resistant starch (MSPrebiotic®) in a pig model of experimental colitis, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada